Business

Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide therapies for cystic fibrosis and other indications, has filed a request to withdraw its registration statement for an initial public offering. The company announced its initial filing for the IPO in August 2015, saying that it planned to raise up to $36 million to support Phase 2 … [Read more...] about Advanced Inhalation Therapies files to withdraw IPO

Smartinhaler maker Adherium has announced an upcoming $8 million AUD ($6 million USD) share placement to Fidelity International, increasing Fidelity's holdings in the company to 10%. The shares will be issued on July 26, 2016. According to Adherium, the purpose of the placement was to raise funds for working capital. Adherium CEO Garth Sutherland commented, … [Read more...] about Fidelity increases its holding in Adherium to 10%

Windtree Therapeutics (formerly Discovery Laboratories) said that it has received an additional $1 million from a Phase 2 Small Business Innovation Research (SBIR) grant initially announced in October 2014. The grant, with a total potential value of $3 million, supports development of the company's aerosolized KL4 surfactant as a treatment for radiation-induced lung … [Read more...] about Windtree Therapeutics gets $1 million for aerosolized KL4 surfactant development

Therapix Biosciences has entered into an agreement with the Hebrew University's technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university's Institute of Drug Research, the company said. The news comes one week after the company, which is developing cannabinoids … [Read more...] about Therapix Biosciences licenses intranasal cannabinoid formulation from Hebrew University

AeroVanc developer Savara Pharmaceuticals has acquired Serendex Pharmaceuticals, which is developing Molgradex inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (PAP). Serendex announced in September 2015 that it was initiating a Phase 2 clinical trial of Molgradex, which is delivered … [Read more...] about Savara Pharmaceuticals acquires Serendex, inhaled molgramostim

In May 2016, Grupo Ferrer announced that it would acquire inhaled drug company Alexza Pharmaceuticals; as of June 21, 2016, the company says, Ferrer Pharma has merged into Alexza Pharmaceuticals, with Alexza now a wholly owned subsidiary of Ferrer. Ferrer already marketed Alexza's Staccato inhaled loxapine in much of the world and had become Alexza's largest … [Read more...] about Ferrer completes merger with Alexza

US generic inhalation solutions manufacturer Nephron Pharmaceuticals has licensed Apotex's generic budesonide inhalation suspension, a generic version of AstraZeneca's Pulmicort Respules, and subsequently launched the product in the US, the company said. Nephron will manufacture, market, and distribute 0.5mg/2mL and 0.25mg/2mL dosage forms. The company's other … [Read more...] about Nephron Pharmaceuticals launches generic budesonide inhalation suspension

MannKind Corporation has announced that it signed an agreement with JDRF (formerly the Juvenile Diabetes Research Foundation) to collaborate on research focused on the use of Afrezza inhaled insulin in pediatric diabetes patients. JDRF is the largest non-profit funder of type 1 diabetes research in the world, according to the organization. The FDA approved … [Read more...] about MannKind partners with JDRF on pediatric use of Afrezza